Healthcare / Drug Manufacturers - GeneralNasdaqCM
$7.99
-0.91 (-10.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $3.1M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$56M
P/E
N/A
•EV/EBITDA
N/A
•ROE
172.6%
↑Gross Margin
65.0%
↑Debt/Equity
-0.60
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+5.1%
FCF CAGR
—
FCF margin
10.2%
FCF / Net income
-0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $30.3M · net income $-358.7M · FCF $3.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $30.3M | $30.3M | $56.6M | $46.7M | $38.0M | $31.3M | $23.6M |
| Net Income | $-358.7M | $-358.7M | $-72.8M | $-114.3M | $-23.4M | $-88.4M | $-47.5M |
| EBITDA | $-357.9M | $-357.9M | $-66.8M | $-109.1M | $-9.8M | $-32.1M | $-31.5M |
| EPS | -36.48 | -36.48 | -8.05 | -44.80 | -5.95 | -23.45 | -12.60 |
| Gross Margin | 65.0% | 65.0% | 70.5% | 66.5% | 71.6% | — | — |
| Operating Margin | -900.1% | -900.1% | -164.0% | -225.6% | -133.1% | -114.4% | -149.7% |
| Net Margin | -1185.8% | -1185.8% | -128.7% | -244.6% | -61.4% | -282.4% | -201.7% |
| Balance Sheet | |||||||
| Debt/Equity | -0.60 | -0.60 | -0.20 | -0.74 | 0.04 | -0.32 | — |
| Current Ratio | 0.08 | 0.08 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $3.1M | $3.1M | $18.7M | $-21.0M | $-23.3M | $-28.7M | $-31.5M |
| Returns | |||||||
| ROE | 172.6% | 172.6% | 37.8% | 66.1% | -64.5% | 39.5% | -253786.6% |
| Valuation | |||||||
| P/B | — | — | — | — | 18.63 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | -46.5% | -46.5% | 21.1% | 22.9% | — | 32.9% | — |
| EPS Growth | -353.2% | -353.2% | 82.0% | -652.9% | — | -86.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+56.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-8.05 → -36.48
Residual
+56.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.